Donanemab (donanemab-azbt)-Kisunla What is the drug?

Donanemab-azbt (donanemab-azbt)-Kisunla is an amyloid beta-directed antibody indicated for the treatment of early symptomatic Alzheimer's disease (AD). Treatment with Kisunla should be initiated in patients with mild cognitive impairment or mild dementia stages of Alzheimer's disease, as this is the population in which treatment is initiated in clinical trials.

Alzheimer's disease is a disease that causes a gradual decline in memory and other cognitive abilities. It is thought to be caused by the accumulation of amyloid beta peptides in the form of amyloid plaques. Kisunla contains donanemab-azbt, a humanized IgG1 antibody that targets a modified form of beta-amyloid plaques known as N3pG. Kisunla is thought to work by helping the body clear excess accumulation of amyloid plaques in the brain, which can cause memory and thinking problems associated with Alzheimer's disease.

Kisunla exists in the form of an injection, which is a sterile, preservative-free, clear to milky white, colorless to slightly yellow to slightly brown solution. The recommended dose may be give Kisunla every four weeks through an intravenous infusion of approximately 30 minutes, but the use of the drug must be under the guidance of a doctor, and patients cannot use the drug at will.

Common adverse reactions (incidence of at least 10% and greater compared to placebo) include ARIA with edema (ARIA-E), ARIA with hemosiderin deposition (ARIA-H) microbleeds, ARIA-H surface siderosis, and headache.

The Kisunla product label has a box warning for amyloid-related imaging abnormality (ARIA), which can be detected with a magnetic resonance imaging (MRI) scan and may appear as temporary swelling or small bleeding spots on or near the surface of the brain. ARIA can be serious and life-threatening events may occur. Kisunla can also cause infusion-related reactions, which can be serious and life-threatening.